According to the WHO, between 2015 and 2050, the proportion of the world’s population over 60 years will nearly double from 12% to 22%. Thus, increasing aging population and rising prevalence of chronic diseases resulted in the organ and tissue loss through diseases and injury leads the development of therapies that can regenerate tissues. Regenerative medicine, an interdisciplinary field that applies engineering and life science principles to promote regeneration, potentially restores diseased and injured tissues and whole organs.
Since the inception of the field several decades ago, a number of regenerative medicine therapies, including those designed for wound healing, heart diseases, and orthopedics applications, have received the Food and Drug Administration (FDA) approval. Specifically, there are various developments in fabricating sophisticated grafts and tissue mimics and technologies for integrating grafts. As collagen and collagen regenerative products helps in regeneration of lost tissues, they are increasingly in demand in medical treatments of various chronic diseases, thereby driving the growth of collagen and gelatin market for regenerative medicine. “Meticulous Research” in its latest publication states that, the “global Collagen and Gelatin Market for Regenerative Medicine is expected to grow at a CAGR of 8.5% from 2017 to 2022 to reach $ 709.9 million by 2022.”
Don’t miss out on business opportunities in Collagen And Gelatin Market For Regenerative Medicine – Global Opportunity Analysis And Industry Forecast (2017-2022)
This growth is primarily driven by the rising prevalence of chronic diseases, rapid growth in aging population, and increasing funding for R & D of regenerative medicines.
According to the Global Health and Aging report presented by the World Health Organization (WHO), the number of people aged 65 or older is projected to grow from an estimated 524 million in 2010 to nearly 1.5 billion in 2050, with most of the increase in developing countries. According to the WHO, between 2015 and 2050, the proportion of the world’s population over 60 years will nearly double from 12% to 22%.
According to the OECD, the expansion of the global elderly population has significant effect on the healthcare systems, and quality of life. Over a period of time, as the life expectancies have steadily increased, there has also been shift in mortality and disability trends. Regenerative medicines are considered to have the potential to dramatically impact care in many areas of established unmet medical use, to improve the standard of care, enhance clinical outcomes & patent quality of life, and improve the economic efficiency of healthcare systems. There is growing number of clinical trials evaluating regenerative medicines for acute and chronic conditions among the aging population such as cardiovascular, and neurological disorders. Collagen networks are one of the cornerstones of regenerative medicine. It finds its application in cardiology as the heart valves are made up of collagen tissue. With aging, there is calcium deposit on the collagen, leading to hardening of the valves. This situation can be treated with the artificial collagen obtained from animal sources. One of the major applications of collagen in healthcare is to prepare the collagen films which acts as a barrier membrane. Such films are used to encapsulate the drugs and commonly used in ophthalmology to deliver the drugs and also used over wounds to make healing rapid and uniform.
Thus, owing to the increasing use of collagen in the regenerative medicines which are further applied in the treatments of aging population drives the growth of collagen & gelatin market for regenerative medicines.
The report provides meticulous analysis of collagen and gelatin market for regenerative medicine on the basis of type, (collagen and gelatin), source, (bovine, porcine, marine, and others), application, (orthopedic, wound care, cardiovascular, and others), and geography.
The key players analyzed in the collagen and gelatin market for regenerative medicine are Collagen Solutions Plc (U.S.), Royal DSM (Netherlands), Symatese (France), NuCollagen LLC (U.S.), GELITA AG (Germany), Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Vornia Biomaterials (Ireland), Advanced BioMatrix (U.S.), Jellagen Pty Ltd (U.K.), EnColl Corporation (U.S.), and XIAMEN HYFINE GELATIN CO., LTD
For detailed Table of Content; Download free sample report here